Cargando…

SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19

Over the past two years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections, resulting in an unprecedented pandemic of coronavirus disease 2019 (COVID-19). As the virus spreads through the population, ongoing mutations and adaptations are b...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Hong-Yu, Wu, Yuyan, Yau, Vicky, Yin, Huan-Xin, Lowe, Scott, Bentley, Rachel, Ahmed, Mubashir Ayaz, Zhao, Wenjing, Sun, Chenyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504858/
https://www.ncbi.nlm.nih.gov/pubmed/36146616
http://dx.doi.org/10.3390/vaccines10091538
_version_ 1784796323227107328
author Liang, Hong-Yu
Wu, Yuyan
Yau, Vicky
Yin, Huan-Xin
Lowe, Scott
Bentley, Rachel
Ahmed, Mubashir Ayaz
Zhao, Wenjing
Sun, Chenyu
author_facet Liang, Hong-Yu
Wu, Yuyan
Yau, Vicky
Yin, Huan-Xin
Lowe, Scott
Bentley, Rachel
Ahmed, Mubashir Ayaz
Zhao, Wenjing
Sun, Chenyu
author_sort Liang, Hong-Yu
collection PubMed
description Over the past two years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections, resulting in an unprecedented pandemic of coronavirus disease 2019 (COVID-19). As the virus spreads through the population, ongoing mutations and adaptations are being discovered. There is now substantial clinical evidence that demonstrates the SARS-CoV-2 variants have stronger transmissibility and higher virulence compared to the wild-type strain of SARS-CoV-2. Hence, development of vaccines against SARS-CoV-2 variants to boost individual immunity has become essential. However, current treatment options are limited for COVID-19 caused by the SARS-CoV-2 variants. In this review, we describe current distribution, variation, biology, and clinical features of COVID-19 caused by SARS-CoV-2 variants (including Alpha (B.1.1.7 Lineage) variant, Beta (B.1.351 Lineage) variant, Gamma (P.1 Lineage) variant, Delta (B.1.617.2 Lineage) variant, and Omicron (B.1.1.529 Lineage) variant and others. In addition, we review currently employed vaccines in clinical or preclinical phases as well as potential targeted therapies in an attempt to provide better preventive and treatment strategies for COVID-19 caused by different SARS-CoV-2 variants.
format Online
Article
Text
id pubmed-9504858
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95048582022-09-24 SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19 Liang, Hong-Yu Wu, Yuyan Yau, Vicky Yin, Huan-Xin Lowe, Scott Bentley, Rachel Ahmed, Mubashir Ayaz Zhao, Wenjing Sun, Chenyu Vaccines (Basel) Review Over the past two years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections, resulting in an unprecedented pandemic of coronavirus disease 2019 (COVID-19). As the virus spreads through the population, ongoing mutations and adaptations are being discovered. There is now substantial clinical evidence that demonstrates the SARS-CoV-2 variants have stronger transmissibility and higher virulence compared to the wild-type strain of SARS-CoV-2. Hence, development of vaccines against SARS-CoV-2 variants to boost individual immunity has become essential. However, current treatment options are limited for COVID-19 caused by the SARS-CoV-2 variants. In this review, we describe current distribution, variation, biology, and clinical features of COVID-19 caused by SARS-CoV-2 variants (including Alpha (B.1.1.7 Lineage) variant, Beta (B.1.351 Lineage) variant, Gamma (P.1 Lineage) variant, Delta (B.1.617.2 Lineage) variant, and Omicron (B.1.1.529 Lineage) variant and others. In addition, we review currently employed vaccines in clinical or preclinical phases as well as potential targeted therapies in an attempt to provide better preventive and treatment strategies for COVID-19 caused by different SARS-CoV-2 variants. MDPI 2022-09-16 /pmc/articles/PMC9504858/ /pubmed/36146616 http://dx.doi.org/10.3390/vaccines10091538 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Liang, Hong-Yu
Wu, Yuyan
Yau, Vicky
Yin, Huan-Xin
Lowe, Scott
Bentley, Rachel
Ahmed, Mubashir Ayaz
Zhao, Wenjing
Sun, Chenyu
SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
title SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
title_full SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
title_fullStr SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
title_full_unstemmed SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
title_short SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
title_sort sars-cov-2 variants, current vaccines and therapeutic implications for covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504858/
https://www.ncbi.nlm.nih.gov/pubmed/36146616
http://dx.doi.org/10.3390/vaccines10091538
work_keys_str_mv AT lianghongyu sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19
AT wuyuyan sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19
AT yauvicky sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19
AT yinhuanxin sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19
AT lowescott sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19
AT bentleyrachel sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19
AT ahmedmubashirayaz sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19
AT zhaowenjing sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19
AT sunchenyu sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19